GIT2 Antibody

What is GIT2 and why is it important in cellular research?

GIT2 (G protein-coupled receptor kinase interacting ArfGAP 2) is a GTPase-activating protein for the ADP ribosylation factor (ARF) family. It functions as a critical scaffold protein that coordinates numerous cellular processes including focal adhesion dynamics, cell migration, and immune responses. The importance of GIT2 extends to multiple biological systems:

• Immune regulation: GIT2 serves as a negative regulator of Toll-like receptor (TLR) signaling by inhibiting the ubiquitination of TRAF6 and recruiting the deubiquitinating enzyme Cylindromatosis (CYLD) .

• Inflammatory response control: GIT2 protects against severe colitis in mice and is essential for the resolution of TLR signaling .

• Cell motility: GIT2 forms complexes with PIX proteins that regulate chemotactic responses and cell migration .

• Tissue expression: GIT2 is expressed in various tissues with particularly notable levels in neuronal and immune cells, including B-cells, T-cells, bone marrow, cerebellum, and epithelium .

Understanding GIT2 biology is essential for research in immunology, cell biology, and inflammation-related pathologies.

How should researchers select the appropriate GIT2 antibody for their specific application?

Selection of an appropriate GIT2 antibody should be systematically approached based on several critical factors:

For example, antibody 67858-1-Ig has been validated for Western Blot (1:5000-1:50000 dilution) and IHC (1:500-1:2000) applications with human and rat samples . For experiments requiring PBS-only buffer (without glycerol or other additives), researchers should consider specialized formats like 67858-1-PBS .

Most importantly, researchers should conduct their own validation studies with positive and negative controls relevant to their experimental system before proceeding with full-scale experiments.

What are the optimal conditions for using GIT2 antibodies in Western blotting applications?

Optimization of Western blotting with GIT2 antibodies requires attention to several technical parameters:

Sample preparation considerations:

• GIT2 has a calculated molecular weight of 95 kDa but is typically observed at 70-85 kDa on Western blots , likely due to post-translational modifications or alternative splicing.

• Efficient cell lysis buffers containing phosphatase and protease inhibitors are recommended to preserve protein integrity.

Protocol optimization:

• Antibody dilution: Titration is essential; recommended ranges vary by manufacturer (e.g., 1:1000 for Cell Signaling antibody , 1:5000-1:50000 for Proteintech antibody ).

• Blocking conditions: 5% non-fat dry milk or BSA in TBST is typically effective.

• Incubation time and temperature: Primary antibody incubation at 4°C overnight often yields optimal results.

• Positive controls: Use cell lysates known to express GIT2 (e.g., A549, K-562, HSC-T6, HEK-293, or HeLa cells) .

Troubleshooting tips:

• If background is high, increase the number/duration of washing steps and optimize antibody concentration.

• If signal is weak, consider longer exposure times or signal enhancement systems.

• For validation experiments, include GIT2 knockout or knockdown samples as negative controls.

How can researchers effectively use GIT2 antibodies in immunohistochemistry studies?

Successful immunohistochemistry with GIT2 antibodies requires careful protocol optimization:

Pre-treatment considerations:

• Antigen retrieval is critical; TE buffer pH 9.0 is suggested for optimal results with some antibodies, though citrate buffer pH 6.0 may be used as an alternative .

• Fixation methods can affect epitope accessibility; formalin-fixed paraffin-embedded (FFPE) samples have been successfully used with antibodies like ab100809 .

Protocol optimization:

• Antibody dilution: Start with manufacturer recommendations (e.g., 1:500-1:2000 for Proteintech antibody ) and adjust based on signal-to-noise ratio.

• Incubation conditions: Typically, room temperature for 1-2 hours or 4°C overnight.

• Detection systems: HRP/DAB systems are commonly used, but fluorescent secondary antibodies may be preferred for co-localization studies.

Tissue-specific considerations:

• GIT2 has been successfully detected in human prostate cancer tissue .

• Human lung carcinoma has been stained using ab100809 at 1/500 dilution .

• Expression patterns may differ significantly between healthy and diseased tissues, requiring appropriate controls.

Validation approaches:

• Include isotype controls to assess non-specific binding.

• Compare staining patterns with published literature and across multiple antibodies.

• When possible, correlate with Western blot or RNA expression data.

How does GIT2 regulate TLR-mediated inflammatory responses, and how can this be studied using GIT2 antibodies?

GIT2 plays a crucial role in negatively regulating TLR-induced inflammatory responses through specific molecular mechanisms:

Key regulatory mechanisms:

• GIT2 inhibits the ubiquitination of TRAF6, a critical step in TLR signaling activation .

• GIT2 recruits the deubiquitinating enzyme CYLD to TRAF6, which terminates TLR-induced NF-κB and MAPK signaling .

• Loss of GIT2 leads to enhanced production of proinflammatory cytokines like IL-6 and TNF-α following TLR stimulation .

Experimental approaches to study this regulation:

• Immunoprecipitation with GIT2 antibodies: To study protein-protein interactions between GIT2, TRAF6, and CYLD.

  • Protocol considerations: Use mild lysis conditions to preserve protein complexes.

  • Utilize both N- and C-terminal targeting antibodies to validate interactions.

• Cellular models with GIT2 knockdown/knockout:

  • Bone marrow-derived macrophages (BMDMs) from GIT2-deficient mice show enhanced TLR-induced cytokine production .

  • Small interfering RNA (siRNA) approaches have been effective in reducing GIT2 expression in cell lines like RBL-FPR cells .

• In vivo models:

  • GIT2-deficient mice show increased susceptibility to DSS-induced colitis and endotoxin shock .

  • These mice exhibit higher levels of proinflammatory cytokines upon LPS challenge .

Data interpretation considerations:

• When analyzing GIT2's role in TLR signaling, researchers should consider the timing of the response, as GIT2 appears to be particularly important for the resolution phase of inflammation.

• The relative contributions of GIT1 versus GIT2 should be assessed, as both proteins are expressed in many cell types and may have overlapping functions .

What approaches can be used to study the GIT2-PIX complex in cell migration and chemotactic responses?

The GIT2-PIX complex plays important roles in regulating cell adhesion, spreading, and chemotactic responses. Methodological approaches to study this complex include:

Biochemical approaches:

• Co-immunoprecipitation: Using GIT2 or PIX antibodies to isolate and characterize the complex composition.

  • In RBL-FPR cells, immunoprecipitation with either anti-GIT1 (recognizing both GIT1 and GIT2) or anti-βPIX antibodies has demonstrated the presence of both GIT1–PIX and GIT2–PIX complexes .

  • Western blotting of immunoprecipitates can reveal the relative abundance of different complex components.

• Protein knockdown studies: siRNA targeting specific components can reveal their functional contributions.

  • Specific siRNAs can efficiently down-regulate the expression of GIT1, GIT2, or PIX proteins to study their individual roles .

  • Quantification of knockdown efficiency is essential for result interpretation.

Cell biological approaches:

• Live cell imaging: To track the dynamics of GIT2-PIX complexes during chemotaxis.

  • Fluorescently tagged GIT2 and PIX proteins can be used to visualize complex formation and trafficking.

• Adhesion and migration assays: To evaluate functional outcomes of complex perturbation.

  • Methods include transwell migration assays, wound healing assays, and time-lapse microscopy to measure cell motility parameters.

Experimental model systems:

• The rat basophilic leukemia RBL-2H3 cell line has been established as a useful model to study agonist-induced chemotaxis and the role of GIT complexes .

• Primary immune cells, especially those involved in directed migration (e.g., neutrophils, macrophages), are also valuable models.

Analytical considerations:

• The composition of GIT-PIX complexes may vary between cell types and in response to different stimuli.

• Both GIT1 and GIT2 may contribute to the observed phenotypes, necessitating careful experimental design to distinguish their specific roles.

How can researchers address discrepancies in GIT2 molecular weight observations?

Researchers frequently encounter molecular weight discrepancies when detecting GIT2 protein, which presents analytical challenges:

Common discrepancies observed:

• The calculated molecular weight of GIT2 is 95 kDa , but it is typically observed at 70-85 kDa in Western blots .

• Cell Signaling Technology's antibody (#6953) detects GIT2 at approximately 85 kDa .

• The UPing Biological antibody (YP-mAb-03902) reports an observed band of 84 kDa .

Potential explanations for these discrepancies:

• Alternative splicing: Multiple GIT2 isoforms have been reported to exist , which may result in proteins of different sizes.

• Post-translational modifications: Phosphorylation, ubiquitination, or proteolytic processing can alter migration patterns.

• Technical factors: Gel percentage, running conditions, and buffer composition can influence protein migration.

Methodological approaches to address these discrepancies:

• Verification with multiple antibodies: Use antibodies targeting different epitopes of GIT2.

• Positive control selection: Include lysates from cells known to express GIT2 (e.g., A549, K-562, HSC-T6, HEK-293, HeLa) .

• Knockout/knockdown controls: Include samples from GIT2-depleted cells to confirm specificity.

• Treatment with phosphatases or deglycosylating enzymes: To determine if post-translational modifications contribute to the observed weight.

Data interpretation recommendations:

What are the critical considerations when comparing results across different studies using various GIT2 antibodies?

When comparing results from studies using different GIT2 antibodies, researchers should consider several factors that might lead to apparent discrepancies:

Antibody characteristics comparison:

Protocol variations:

• Fixation methods (for IHC/IF) significantly impact epitope availability.

• Sample preparation (lysis buffers, detergents) affects protein extraction efficiency.

• Blocking reagents influence background and specificity.

Experimental model differences:

• GIT2 expression levels vary across tissues and cell types .

• Expression patterns may differ between normal and disease states.

• GIT1/GIT2 ratio varies between cell types and might influence interpretation .

Validation and standardization approaches:

• Perform side-by-side comparisons of different antibodies when possible.

• Include appropriate positive and negative controls.

• Consider complementary detection methods (e.g., mass spectrometry, RNA-seq).

• Clearly document antibody validation methods in publications.

How can researchers effectively study the role of GIT2 in inflammatory bowel disease models?

Based on evidence that GIT2 protects against colitis , researchers interested in studying its role in inflammatory bowel disease (IBD) models should consider these methodological approaches:

In vivo experimental models:

• DSS-induced colitis: GIT2-deficient mice show increased susceptibility to DSS-induced colitis compared to wild-type mice .

  • Disease assessment parameters: weight loss, colon length, histological scoring, and cytokine production.

  • Analytical considerations: Timing of assessment is critical as GIT2 appears particularly important for resolution of inflammation.

• Bone marrow chimeras: To distinguish between contributions of hematopoietic vs. non-hematopoietic GIT2 expression.

  • Experimental design: Transfer of wild-type or GIT2-deficient bone marrow into irradiated recipients.

• Cell-type specific knockout models: To determine which cell populations mediate GIT2's protective effects.

  • Target populations: Intestinal epithelial cells, macrophages, dendritic cells, and T cells.

Molecular mechanistic investigations:

• TLR signaling assessment: Measure activation of NF-κB and MAPK pathways in colonic tissues and isolated cells.

  • Techniques: Western blotting with phospho-specific antibodies, immunohistochemistry, and flow cytometry.

• TRAF6 ubiquitination analysis: Examine GIT2's effect on TRAF6 ubiquitination status.

  • Methods: Immunoprecipitation of TRAF6 followed by ubiquitin Western blotting.

• GIT2-CYLD interaction studies: Investigate the recruitment of CYLD to TRAF6 by GIT2.

  • Approaches: Co-immunoprecipitation, proximity ligation assays, and FRET-based techniques.

Translational applications:

• Human tissue analysis: Examine GIT2 expression in IBD patient biopsies compared to controls.

  • Consider: Disease activity, treatment status, and disease subtype (Crohn's vs. ulcerative colitis).

• Genetic association studies: Analyze GIT2 polymorphisms or expression levels in IBD cohorts.

• Therapeutic targeting approaches: Develop strategies to enhance GIT2 function or target downstream pathways.

What are the emerging techniques for studying GIT2 protein-protein interactions in complex cellular environments?

As research into GIT2 biology advances, new methodologies are emerging to study its interactions in more physiologically relevant contexts:

Advanced protein interaction methodologies:

• Proximity labeling approaches: BioID or APEX2 fused to GIT2 to identify proteins in its vicinity within living cells.

  • Advantages: Captures transient and weak interactions in native cellular environments.

  • Applications: Identifying novel GIT2 interaction partners during inflammatory responses.

• CRISPR-based tagging: Endogenous tagging of GIT2 to avoid overexpression artifacts.

  • Considerations: Tag placement to avoid functional interference.

• Single-molecule imaging techniques: To visualize GIT2 complex dynamics in real-time.

  • Methods: Total internal reflection fluorescence (TIRF) microscopy or lattice light-sheet microscopy.

  • Applications: Tracking GIT2-PIX complex formation and trafficking during chemotaxis.

Structural biology approaches:

• Cryo-electron microscopy: To determine the structure of GIT2 complexes.

  • Challenges: Complex purification and stability.

• Hydrogen-deuterium exchange mass spectrometry: To map interaction interfaces and conformational changes.

  • Applications: Understanding how GIT2 interacts with TRAF6 and CYLD.

Systems biology integration:

• Multi-omics approaches: Combining proteomics, transcriptomics, and interactomics data.

  • Example: Correlating GIT2 interactome changes with transcriptional responses during inflammation resolution.

• Mathematical modeling: To predict GIT2 signaling dynamics in complex networks.

  • Applications: Understanding how GIT2 contributes to the switch from pro- to anti-inflammatory states.

Validation in primary cells and tissues:

• Patient-derived organoids: For studying GIT2 function in human disease models.

• Intravital imaging: To observe GIT2 dynamics in live animals during inflammatory responses.

  • Technical considerations: Requires fluorescently tagged GIT2 and specialized microscopy.

These emerging approaches offer exciting opportunities to advance our understanding of GIT2 biology in normal physiology and disease states, potentially revealing new therapeutic opportunities for inflammatory diseases.